Stock ACAD ACADIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Real-time Estimate Cboe BZX
Other stock markets
 03:27:33 2024-05-10 pm EDT 		5-day change 1st Jan Change
15.34 USD +0.82% Intraday chart for ACADIA Pharmaceuticals Inc. -9.97% -50.97%
05:38pm UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating MT
04:04pm Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating
MT
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating
MT
Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million
MT
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
BU
Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $26, Keeps Hold Rating
MT
ACADIA Pharmaceuticals : Corporate Presentation (1Q24 Earnings)
PU
Transcript : ACADIA Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (ACAD) ACADIA PHARMACEUTICALS Reports Q1 Revenue $205.8M, vs. Street Est of $208.6M
MT
Acadia: Q1 Earnings Snapshot
AQ
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
BU
ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the Full Year 2024
CI
ACADIA Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating
MT
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
BU
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
BU
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada
MT
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada
MT
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
BU
Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACAD Stock
  4. News ACADIA Pharmaceuticals Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW